glp 1 sglt2 Diabetic Agents, From Metformin to Inhibitors and GLP1 Receptor Agonists: JACC Focus Seminar Cardiovascular benefits of SGLT2 inhibitors

Description

Not all GLP-1 products are FDA-approved

NRD per 1000 people 5.57 (6.61 to 4.53)), cannabis use (0.86 (0.81 to 0.90), NRD 2.25 (3.00 to 1.50)), cocaine use (0.80 (0.72 to 0.88), NRD 0.97 (1.37 to 0.57)), nicotine use (0.80 (0.74 to 0.87), NRD 1.64 (2.19 to 1.09)), and opioid use (0.75 (0.67 to 0.85), NRD 0.86 (1.19 to 0.52)), and other SUDs (0.87 (0.81 to 0.94), NRD 1.12 (1.68 to 0.55)) and composite outcome of all incident SUDs (0.86 (0.83 to 0.88), NRD 6.61 (7.95 to 5.26))

Suggested Use: For adult use only

Gingivitis and periodontitis are the causes of bleeding gums which result in pain and swollen gums.

GLP-1RAs reduce events linked to atherogenic cardiovascular disease (especially ischemic stroke) and also renal outcomes (FLOW trial with semaglutide), with a limited effect on heart failure